Synopsis
Anupam Rasayan, a leading player in the specialty chemicals sector, has announced its Q1FY26 results showcasing strong annual growth but a mild sequential slowdown.
This Chemical company continues to benefit from higher demand in its product portfolio and improved operational efficiencies, although short-term challenges have impacted quarter-on-quarter performance.
With market capitalization of Rs. 12,679 cr, the shares of Anupam Rasayan India Ltd are currently trading at Rs. 1,154.20 apiece, increasing 4% from its previous close of Rs. 1,146.80, making today’s high of Rs. 1,197 apiece.
Q1FY26 Results
Anupam Rasayan delivered exceptional year-on-year (YoY) performance in Q1FY26, with sales rising 91% to Rs. 486 crore from Rs. 254 crore, EBIDT surging 134% to Rs. 124 crore from Rs. 53.2 crore, net profit skyrocketing 768% to Rs. 48.5 crore from Rs. 12.2 crore, and EPS jumping 761% to Rs. 3.10 from Rs. 0.36.
However, on a quarter-on-quarter (QoQ) basis, the company saw a moderation in performance, as sales slipped 2.8% from Rs. 500 crore in Q4FY25, EBIDT declined 13.9% from Rs. 144 crore, net profit fell 22.9% from Rs. 62.9 crore, and EPS dropped 23.5% from Rs. 4.05, indicating some sequential pressure despite robust annual growth.
Anupam Rasayan India Ltd. is a leading specialty chemicals manufacturer engaged in custom synthesis and production of complex molecules for global and domestic clients. Its operations span two key segments which are life-science-related specialty chemicals, catering to agrochemicals, personal care, and pharmaceuticals, and performance materials, serving polymer, electronics, and high-performance applications.
With six advanced manufacturing facilities in Gujarat, strong R&D capabilities, and a focus on sustainable practices like renewable energy use and zero liquid discharge, the company plays a significant role in supplying high-value chemicals across diverse industries.
Managing Director’s Message
In Q1FY26, Anupam Rasayan reported Rs. 491 crore in total revenue, up 89% YoY, driven by strong performance in pharma, polymer, and a recovering agrochemical segment. Exports contributed 58% of revenue, with the US and Japan showing positive trends. Two new deals with multinational firms have boosted the order book to Rs. 14,646 crore, underscoring strong growth momentum.
Written by Manideep Appana
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
